Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 07, 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate governance event rather than a financial statement.
Material Changes
The primary material change disclosed is a Change of Director's Interest involving D. Stamler, as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves to incorporate the Director's Interest Notice into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 for specific details regarding the nature and magnitude of D. Stamler's change in interest.
- Verify the impact of this change on the company's governance structure.
- Confirm the status of the referenced Registration Statements (S-8 and F-3) for potential capital raising activities.